New pill offers hope for chronic ITP patients in phase 3 trial
Disease control
Completed
This study tested a daily pill called HMPL-523 (sovleplenib) in 272 adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants had failed at least one prior treatment. The goal was to see if the d…
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 17, 2026 06:47 UTC